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Abstract
Background: Comparing the effectiveness of interventions is now a requirement for regulatory
approval in several countries. It also aids in clinical and public health decision-making. However, in
the absence of head-to-head randomized trials (RCTs), determining the relative effectiveness of
interventions is challenging. Several methodological options are now available. We aimed to
determine the comparative validity of the adjusted indirect comparisons of RCTs with the mixed
treatment comparison approach.
Methods: Using systematic searching, we identified all meta-analyses evaluating more than 3
interventions for a similar disease state with binary outcomes. We abstracted data on each clinical
trial including population n and outcomes. We conducted fixed effects meta-analysis of each
intervention versus mutual comparator and then applied the adjusted indirect comparison. We
conducted a mixed treatment meta-analysis on all trials and compared the point estimates and 95%
confidence/credible intervals (CIs/CrIs) to determine important differences.
Results: We included data from 7 reviews that met our inclusion criteria, allowing a total of 51
comparisons. According to the a priori consistency rule, we found 2 examples where the analytic
comparisons were statistically significant using the mixed treatment comparison over the adjusted
indirect comparisons and 1 example where this was vice versa. We found 6 examples where the
direction of effect differed according to the indirect comparison method chosen and we found 9
examples where the confidence intervals were importantly different between approaches.
Conclusion: In most analyses, the adjusted indirect comparison yields estimates of relative
effectiveness equal to the mixed treatment comparison. In less complex indirect comparisons,
where all studies share a mutual comparator, both approaches yield similar benefits. As
comparisons become more complex, the mixed treatment comparison may be favoured.
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Acknowledging their enormous value for health interven-
tion decision-making, clinicians, drug manufacturers, reg-
ulatory agencies and the public are now requiring meta-
analysis to identify the most effective intervention among
a range of alternatives.[1] As meta-analysis grows in pop-
ularity, investigators have endeavoured to further enhance
its usefulness by proposing extensions meant to accom-
modate a number of challenges. One important challenge
is choosing from a number of potentially competing inter-
ventions, not all of which have been subject to direct com-
parison in properly conducted randomized trials; herein
referred to as indirect comparisons.
Until recently, meta-analysis addressed indirect compari-
sons using flawed methods that examined only interven-
tion groups and ignored control event rates.[2] In the last
decades, methodological advances,[3] most notably, the
adjusted indirect comparison, first reported in 1997,[4]
and the mixed treatment comparison, first reported in
2003, [5] have provided more sophisticated methods for
quantitatively addressing indirect comparisons.
The adjusted indirect comparison, first reported by Bucher
et al.,[4] enables one to construct an indirect estimate of
the relative effect of two interventions A and B, by using
information from randomized trials comparing each of
these interventions against a common comparator C (e.g.,
placebo or standard treatment). In this approach, direct
estimates of the relative effects of A versus C and B versus
C, together with appropriate measures of uncertainty, are
obtained using standard pairwise meta-analysis. These
estimates are then appropriately combined to produce an
indirect estimate of the relative effect of A versus B. A suit-
able measure of uncertainty for the indirect estimate is
also produced.
The multiple treatment approaches, based on developing
methods by several investigators,[6,7]most recently Lu
and Ades,[8] is a generalization of standard pairwise
meta-analysis for A versus B trials, to data structures that
include, for example, A versus B, B versus C, and A versus
C trials. This approach, which can only be applied to con-
nected networks of randomised trials, has two important
roles: (1) strengthening inference concerning the relative
efficacy of two treatments, by including both direct and
indirect comparisons of these treatments, and (2) facilitat-
ing simultaneous inference regarding all treatments, in
order to simultaneously compare, or even rank, these
treatments.[8]
The adjusted indirect comparison and the mixed treat-
ment comparison approach can be implemented through
a range of methods, including frequentist, Bayesian and
various subspecies of each.[9]
The basic assumptions underlying the adjusted indirect
comparison and mixed treatment comparison approaches
are similar to but more complex than the assumptions
concerning the standard meta-analysis approach. Just like
standard meta-analysis, both approaches rely on the
homogeneity assumption, which states that trials are suf-
ficiently homogeneous to be quantitatively combined. In
addition, both approaches require a similarity assump-
tion - namely, that trials are similar for moderators of rel-
ative treatment effect. The mixed treatment comparison
approach also requires a consistency assumption, which is
needed to quantitatively combine direct and indirect evi-
dence.[10]
Both adjusted indirect comparison and mixed treatment
comparison approaches to evaluating the relative impact
of multiple alternative treatments have strengths and
weaknesses.[11] The multiple treatment comparison uses
both direct and indirect evidence. The adjusted indirect
method is comparatively simple and interpretable by
users, but requires that an intervention can only be com-
pared with another intervention when they share a
mutual comparator (eg. placebo).[4] The mixed treatment
comparison may be less intuitive as it can permit compar-
isons when interventions do not share a comparator as it
creates a conceptual network[12,13] as well as borrows
power from trials that were not available for use in the
adjusted indirect comparison approach.[14]
Meta-analysts, agencies, and readers are now attempting
to gain further insight into the relative merits of the two
approaches.[15] New US government initiatives to deter-
mine the comparative effectiveness of interventions
require the use of indirect evidence, but do not provide
guidance on what approach to use. Others, such as UK's
National Institute for Clinical Excellence (NICE) provide
advice on the particular use of mixed treatment compari-
sons and adjusted indirect comparisons.[15] To further
elucidate the relative performance of the adjusted indirect
comparison and mixed treatment comparison methods,
we applied both approaches to different comparative
studies that evaluated the effectiveness of multiple com-
peting treatments for diverse health conditions. Our
objective is to determine whether the adjusted indirect
comparison approach generates results comparable to
those produced by the mixed treatment comparison
approach. We aim to determine if there are circumstances
where one method is preferable.
Methods
Eligibility Criteria
We included systematic reviews of randomized clinical tri-
als involving at least 4 different treatments (i.e., health
interventions used for treatment or prevention of the
same medical condition), as networks of three healthPage 2 of 12
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study.[2,3,16] If a treatment consisted of several doses, we
considered all doses to be equivalent. We also considered
no-treatment and placebo to be equivalent. Whenever
present, we excluded cluster randomized trials from these
systematic review along with crossover trials and trials
reporting only continuous outcomes.
Search Strategy
We (EM, OE) searched independently, in duplicate,
PubMed from inception to January 2008 using the follow-
ing search strategy: "network AND meta-analysis," "mixed
treatment AND meta-analysis," "indirect comparison,"
"indirect AND meta-analysis," and "mixed treatment
AND meta-analysis." Our search was limited to English-
language articles. We supplemented our search strategy
and findings from a review of network geometry of stud-
ies[13] and from our own meta-analyses of multiple treat-
ments (Perri D, O'Regan C, Cooper C, Nachega JB, Wu P,
Tleyjeh I, Philips P, Mills EJ: Antifungal treatment for sys-
temtic candida infectons: A mixed treatment compari-
son meta-analysis. Unpublished).[17]
Data Abstraction
We (EM, OE) abstracted independently, in duplicate,
information addressing the systematic review aims,
number of trials per comparison, number of individuals
with each specific outcome and number of individuals
randomised to each intervention.
Statistical analyses
We first plotted the geometric networks of comparisons to
graphically display what indirect comparisons our analy-
ses aimed to assess.
We conducted the mixed treatment comparisons using
fixed effects models similar to those introduced by Lu and
Ades.[8] Although several definitions exist, we interpret
that the fixed effects approach assumes that there is a sin-
gle true value underlying all the study results. That is,
those studies would yield similar effects regardless of the
particular population enrolled, the intervention chosen,
and the strategy for measuring the outcome of interest. A
fixed effect model aims to estimate the common-truth
effect and the uncertainty around this estimate.[18] We
considered separate models for each outcome category
(i.e., mortality, response) using approximately non-
informed priors. We used these models as a basis for
deriving the odds ratio [OR] for each treatment compari-
son with 95% Credible Intervals (CrIs) - the Bayesian
equivalent of a classical confidence interval.
We estimated the posterior densities for all unknown
model parameters using MCMC (Markov chain Monte
Carlo) simulation, as implemented in the software pack-
age WinBUGS Version 1.4. Specifically, we simulated two
MCMC chains starting from different initial values of
select unknown parameters. Each chain contained 20,000
burn-in iterations followed by 20,000 update iterations.
We assessed convergence by visualizing the histories of
the chains against the iteration number; overlapping his-
tories, that appeared to mix with each other, provided an
indication of convergence. We based our inferences on the
(convergence) posterior distributions of the relevant
parameters. In particular, we estimated the OR for a given
treatment comparison by exponentiating the mean of the
posterior distribution of the log OR, and constructed the
corresponding 95% CrI by exponentiating the 2.5th and
97.5th percentiles of the posterior distribution of the log
OR. Other parameters were estimated as means of corre-
sponding posterior distributions.
We measured the goodness of fit of our models to the data
by calculating the residual deviance. Residual deviance
was defined as the difference between the deviance for the
fitted model and the deviance for the saturated model,
where the deviance uses the likelihood function to meas-
ure the fit of the model to the data. Under the null
hypothesis that the model provides an adequate fit to the
data, the residual deviance is expected to have a mean
equal to the number of unconstrained data points.
For our relative effect sizes used in the adjusted indirect
comparison analyses, we used the same data as for the
mixed treatment comparison analyses. We conducted
multiple meta-analyses of head-to-head comparisons to
obtain ORs and 95% Confidence Intervals [95% CIs]. As
with the mixed treatment analyses, we applied the fixed
effects method. Once we obtained the summary estimates
of pooled head-to-head evaluations with CIs, we applied
the adjusted indirect comparison approach.[4]
For each systematic review, we determined if there were
important inconsistencies between the adjusted indirect
comparison and mixed treatment comparison approaches
by comparing the 95% CrI produced by the former
approach against the 95% CI produced by the latter
approach for the OR of each feasible treatment compari-
son. We diagnosed inconsistency by assessing departures
from an a priori determined consistency rule stating that
the lower and upper endpoints of the two types of inter-
vals should not differ by more than 0.25 and 0.75, respec-
tively, and the estimated ORs should not differ by more
than 0.5. EM and IG performed all statistical analyses.
Results
We identified 44 potentially relevant systematic reviews of
the effectiveness of multiple treatments for different
health conditions, including two of our own reviews that
were ongoing during the search period (Perri D, O'ReganPage 3 of 12
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EJ: Antifungal treatment for systemtic candida infec-
tons: A mixed treatment comparison meta-analysis.
Unpublished).[17] We narrowed down the scope of our
search by excluding 13 reviews that incorporated fewer
than 4 treatments, 9 reviews that excluded eligible data for
comparisons, 3 reviews that did not create a network of
comparisons, and 12 reviews that did not provide data on
individual outcomes in each study. In total, we included
seven systematic reviews in our analyses (Perri D, O'Regan
C, Cooper C, Nachega JB, Wu P, Tleyjeh I, Philips P, Mills
EJ: Antifungal treatment for systemtic candida infec-
tons: A mixed treatment comparison meta-analysis.
Unpublished) [4,17,19-22]with three different types of
network structures: (I) star-network, having a common
comparator and containing no loops (figures 1, 2, 3), (II)
single-loop network (figures 4 and 5), containing only
one loop, and (III) multi-loop network, containing two or
more loops (figures 6 and 7). All seven reviews were pub-
lished between the years 1997 to present.
Number of comparisons
The seven systematic reviews retained in our analyses
included between 4 and 8 treatments. Four reviews did
not have a no-treatment control intervention (Perri D,
O'Regan C, Cooper C, Nachega JB, Wu P, Tleyjeh I, Philips
P, Mills EJ: Antifungal treatment for systemtic candida
infectons: A mixed treatment comparison meta-analy- sis. Unpublished). [4,20,22] The number of trials
included in the seven systematic reviews ranged from 10
to 29. Two reviews had insufficient mutual comparator
arms to allow the adjusted indirect comparison evalua-
tion on each intervention (Perri D, O'Regan C, Cooper C,
Star-network of evidence formed by the seven stent treat-ments on target lesion r vascularization event rates,toge her with information n the numb r of trials, umber of patie ts and number of e ts per (direct) tre tment com-r sonFi ur  1
Star-network of evidence formed by the seven stent 
treatments on target lesion revascularization event 
rates, together with information on the number of 
trials, number of patients and number of events per 
(direct) treatment comparison. Each treatment is a 
node in the network. The links between nodes are trials or 
pairs of trial arms. The numbers along the link lines indicate 
the number of trials or pairs of trial arms for that link in the 
network.
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1 5 
5 
4 
   
      
Comparison Number of Trials  
per Comparison 
Number of Patients  
per Comparison 
Number of Events 
per Comparison 
A vs. B 1 119 vs. 241 11 vs. 49 
A vs. C 2 58 vs. 48 7 vs. 2 
A vs. D 1 50 vs. 100 6 vs. 11 
A vs. E 4 643 vs. 818 71 vs. 58 
A vs. F 5 1,179 vs. 1,178 183 vs. 55 
A vs. G 5 999 vs. 1,007 205 vs. 44 
 A
 B
 G
 C
 D
 E F
A = BMS 
B = AES 
C = Polymeric EES 
D = MES 
E = Apolymeric PES 
F = Polymeric PES 
G = Polymeric SES 
Star-network of evidence formed by the treatments Placebo, Ketoprofen, Ibuprofen, Felbinac, Piroxicam, Indometh in and Other NSAID, together with inf rm tion on the num erof rials, num er of patients and number of eve ts per (direct) comparis nFigur 2
Star-network of evidence formed by the treatments 
Placebo, Ketoprofen, Ibuprofen, Felbinac, Piroxicam, 
Indomethacin and Other NSAID, together with 
information on the number of trials, number of 
patients and number of events per (direct) compari-
son.
3 
6 
5 
3 
   
      
Direct 
Comparison 
Number of Trials  
per Comparison 
Number of Patients  
per Comparison 
Number of Events 
per Comparison 
A vs. B 6 260 vs. 258 101 vs. 203 
A vs. C 5 186 vs. 183  67 vs. 112 
A vs. D 3 203 vs. 210 57 vs. 62 
A vs. E 3 194 vs. 283 85 vs. 184 
A vs. F 3 110 vs. 197 39 vs. 95 
A vs. G 9 377 vs. 397 166 vs. 292 
 B
 A
 E
 G
9 
 F
 C
 D
3 
A = Placebo 
B = Ketoprofen 
C = Ibuprofen 
D = Felbinac 
E = Piroxicam 
F = Indomethacin 
G = Other NSAID 
Star-network of evidence formed by the four statin treat-ments and the placebo treatment in primary preven ion of cardiovascular mortality, together wi  inf rmatio on thenumber of rials, numbe  f pati nts and number of events pe  (di ect) co paris nFigur  3
Star-network of evidence formed by the four statin 
treatments and the placebo treatment in primary 
prevention of cardiovascular mortality, together with 
information on the number of trials, number of 
patients and number of events per (direct) compari-
son.
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2 
11
   
   
Comparison Number of Trials  
per Comparison 
Number of Patients  
per Comparison 
Number of Events 
per Comparison 
A vs. B 4 7,860 vs. 8,047 149 vs. 134 
A vs. C 2 1,337 vs. 1,333 68 vs. 53 
A vs. D 11 18,666 vs. 19,123  581 vs. 529 
A vs. E 2 3,760 vs. 3,764 31 vs. 17 
 A
 B  C
 D E
A = Placebo 
B = Atorvastatin 
C = Fluvastatin 
D = Pravastatin 
E = Lovastatin Page 4 of 12
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gal treatment for systemtic candida infectons: A mixed
treatment comparison meta-analysis. Unpublished).
[21] There were no three or greater-armed trials found in
any of the seven systematic reviews.
Analyses 1-3 (figures 1, 2, 3) represent star-shaped com-
parisons whereby each intervention shares a mutual com-
parator. Analysis 4 and 5 (figures 4 and 5) are networks
with a single loop demonstrating that multiple interven-
tions have been compared, but do not necessarily have a
mutual comparator across treatment. Analyses 6 and 7
(figures 6 and 7) are multi-loop comparisons whereby
more treatments exist that have not had mutual compara-
tors.
Analysis 1. Drug-eluting stents compared to bare-metal stents on 
target lesion revascularization event rates[22]
We evaluated the impact of drug-eluting stents compared
to bare-metal stents on the outcome of target lesion revas-
Single-loop network of evidence formed by the four antibi-otic and antiseptic treatments, togeth r with information on the number of trials, nu ber of patients and number of ev nts per (direct) treat ent omparisonFigure 4
Single-loop network of evidence formed by the four 
antibiotic and antiseptic treatments, together with 
information on the number of trials, number of 
patients and number of events per (direct) treat-
ment comparison.
2 
 83 
 5
   
      
Direct 
Comparison 
Number of Trials  
per Comparison 
Number of Patients  
per Comparison 
Number of Events 
per Comparison 
A vs. B 2 99 vs. 98 80 vs. 35 
B vs. C 8 322 vs. 356 60 vs. 98 
B vs. D 3 114 vs. 149 45 vs. 117 
C vs. D 5 176 vs. 157 73 vs. 108 
 A
 B
 D  C
A = No Treatment 
B = Topical Quinolone Antibiotic 
C = Topical Non-Quinolone Antibiotic
D = Topical Antiseptic 
Single-loop network of evidence formed by five antifungal treatments, together with information on the number of tri-als, number of pati nts and number of events per (di ect) com risonFigure 5
Single-loop network of evidence formed by five anti-
fungal treatments, together with information on the 
number of trials, number of patients and number of 
events per (direct) treatment comparison.
1 
4 
2 2 
   
      
Direct 
Comparison 
Number of Trials  
per Comparison 
Number of Patients  
per Comparison 
Number of Events 
per Comparison 
A vs. B 4 232 vs. 245 28 vs. 28 
A vs. C 2 81 vs. 110 9 vs. 6 
A vs. D 1 41 vs. 43 5 vs. 3 
A vs. E 2 88 vs. 49 4 vs. 4 
B vs. C 1 91 vs. 97 7 vs. 12 
 B
 A  C
 D
 E
1 
A = Control 
B = Fluconazol 
C = Itraconazole 
D = Liposomal Amphotericin B 
E = Ketaconazole 
Multi-loop network of evidence formed by the four treat-ments f r pr vention of Pn umocystis carinii pne moni , toge her with inf rmation on the nu ber of trials, number of patients and number of events per (dir ct) reatmen  com-r sonFi ur  6
Multi-loop network of evidence formed by the four 
treatments for prevention of Pneumocystis carinii 
pneumonia, together with information on the 
number of trials, number of patients and number of 
events per (direct) treatment comparison.
2 
2 6 
3 
9 
   
Direct 
Comparison 
Number of Trials  
per Comparison 
Number of Patients  
per Comparison 
Number of Events 
per Comparison 
A vs. B 9 681 vs. 613 26 vs. 74 
A vs. C 2 315 vs. 335 43 vs. 42 
A vs. D 6 488 vs. 480 13 vs. 46 
B vs. C 3 300 vs. 268 35 vs. 29 
B vs. D 2 418 vs. 464 23 vs. 22 
B 
A C D 
A = TMP-SX
B = AP 
C = D 
D = D/P 
Multi-loop network of evidence formed by the eight antifun-gal treatme ts, t gether with information on th  number of trials, nu ber of patients and number of events per (direct)eatment compa isonFigure 7
Multi-loop network of evidence formed by the eight 
antifungal treatments, together with information on 
the number of trials, number of patients and number 
of events per (direct) treatment comparison.
1 
1 
1 
2 
   F   D    E
B   C 
 A  H    
 G     
Direct 
Comparison 
Number of Trials  
per Comparison 
Number of Patients  
per Comparison 
Number of Events 
per Comparison 
A vs. C 10 669 vs. 653 157 vs. 183 
A vs. G 1 118 vs. 127 37 vs. 29 
B vs. C 1 109 vs. 115 39 vs. 38 
B vs. D 1 556 vs. 539 61 vs. 75 
B vs. F 1 193 vs. 402 51 vs. 125 
C vs. E 1 122 vs. 248 51 vs. 88 
C vs. H 2 197 vs. 195 31 vs. 23 
D vs. E 1 422 vs. 415 25 vs. 33 
D vs. F 1 247 vs. 247 108 vs. 106 
1 
1 
1 
10
1 
A = Fluconazole 
B = Caspofungin 
C = Amphotericin B Deoxycholate 
D = Amphotericin B Liposomal 
E = Voriconazole 
F = Micafungin 
G = Anidulafungin 
H = Itraconazole Page 5 of 12
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domised trials comparing 7 different treatments. Figure 1
displays the network of evidence available from these tri-
als. Table 1 shows the results of the pairwise treatment
comparisons when using direct, head-to-head data (in
bold), the mixed treatment approach and the adjusted
indirect comparison approach. In a single instance, the
mixed treatment comparison approach found a signifi-
cant difference between the effects of two treatments
when the adjusted indirect comparison approach did not.
According to the a priori consistency rule, the estimated
ORs and associated uncertainty intervals were impor-
tantly different between the two approaches for only four
pairwise treatment comparisons.
Analysis 2. NSAIDS for acute pain[19]
We evaluated the effects of 7 different interventions for
acute pain from 29 trials that included 58 trial arms, for a
possible 21 comparisons. See Figure 2 and Table 2. We
found no important distinctions between the adjusted
indirect comparison and mixed treatment comparison
approaches.
Analysis 3. Statins for the primary prevention of cardiovascular 
mortality[17]
We evaluated the role of 4 statin interventions compared
to placebo/standard care for the prevention of cardiovas-
cular mortality in primary prevention of cardiovascular
disease populations. See Figure 3 and Table 3. There were
18 trials included, from 38 arms, allowing for a possible
10 comparisons. We found no major discrepancies
between the two comparative approaches.
Analysis 4. Topical treatment for treatment of ear discharge at 1 and 
2 weeks [21]
We evaluated the role of topical antibiotics for the preven-
tion of ear discharge for patients with eardrum perfora-
tions using 18 2-arm randomised trials comparing 4
different treatments. Figure 4 displays the network of evi-
dence available from these trials. The results of the 2 pair-
wise treatment comparisons performed via the adjusted
indirect comparison approach and 6 pair-wise treatment
comparisons performed via the mixed treatment compar-
ison approach are shown in Table 4. In one circumstance,
the mixed treatment comparison approach found a statis-
Table 1: Drug-eluting stents compared to bare-metal stents on revascularization status[22].
Treatment Comparison Mixed Treatment Comparison Adjusted Indirect Comparison
Odds Ratio 95% Credible Interval Odds Ratio 95% Confidence Interval
AES vs. BMS 2.61 (1.32, 5.44) 2.51 (1.22, 5.56)
Polymeric EES vs. BMS 0.31 (0.04, 1.63) 0.37 (0.06, 2.14)
MES vs. BMS 0.93 (0.32, 2.88) 0.91 (0.28, 3.19)
Apolymeric PES vs. BMS 0.64 (0.44, 0.93) 0.64 (0.44, 0.93)
Polymeric PES vs. BMS 0.26 (0.19, 0.36) 0.27 (0.20, 0.37)
Polymeric SES vs. BMS 0.17 (0.12, 0.24) 0.20 (0.13, 0.30)
Polymeric EES vs. AES 0.12 (0.01, 0.73) 0.14 (0.02, 1.04)*
MES vs. AES 0.36 (0.10, 1.34) 0.36 (0.09, 1.44)
Apolymeric PES vs. AES 0.25 (0.11, 0.54) 0.25 (0.11, 1.57)
Polymeric PES vs. AES 0.10 (0.05, 0.21) 0.10 (0.04, 0.23)
Polymeric SES vs. AES 0.07 (0.03, 0.14) 0.07 (0.03, 0.18)
MES vs. Polymeric EES 3.00 (0.40, 30.08) 2.45 (0.28, 21.48)***
Apolymeric PES vs. Polymeric EES 2.06 (0.37, 16.49) 1.72 (0.26, 11.08)***
Polymeric PES vs. Polymeric EES 0.85 (0.15, 6.79) 0.72 (0.11, 4.61)***
Polymeric SES vs. Polymeric EES 0.56 (0.10, 4.53) 0.54 (0.08, 3.50)***
Apolymeric PES vs. MES 0.69 (0.21, 2.16)) 0.70 (0.20, 2.42)
Polymeric PES vs. MES 0.28 (0.09, 0.87) 0.29 (0.08, 1.00)
Polymeric SES vs. MES 0.19 (0.06, 0.58 0.21 (0.06, 0.77)
Polymeric PES vs. Apolymeric PES 0.41 (0.25, 0.67) 0.42 (0.26, 0.68)
Polymeric SES vs. Apolymeric PES 0.27 (0.16, 0.45) 0.31 (0.17, 0.55)
Polymeric SES vs. Polymeric PES 0.66 (0.41, 1.05) 0.74 (0.43, 1.25)
Bolded text denotes head-to-head meta-analysis evaluations. * Mixed treatment method identifies a significant effect, adjusted indirect comparison 
does not, adjusted indirect comparison identifies significant effect, mixed treatment comparison does not. ** Direction of effect differs between 
approaches, ***Important effect size differences.Page 6 of 12
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Table 2: NSAIDS for acute pain[19].
Treatment Comparison Mixed Treatment Comparison Adjusted Indirect Comparison
Odds Ratio 95% Credible Interval Odds Ratio 95% Confidence Interval
Ketoprofen vs. Placebo 6.55 (4.35, 9.95) 6.06 (4.07, 9.04)
Ibuprofen vs. Placebo 2.95 (1.92, 4.57) 2.70 (1.78, 4.09)
Felbinac vs. Placebo 3.02 (2.01, 4.58) 2.91 (1.94, 4.39)
Piroxicam vs. Placebo 2.75 (1.86, 4.08) 2.65 (1.80, 3.90)
Indomethacin vs. Placebo 1.60 (0.99, 2.62) 1.58 (0.97, 2.57)
Other NSAID vs. Placebo 3.74 (2.73, 5.13) 3.31 (2.46, 4.45
Ibuprofen vs. Ketoprofen 0.45 (0.25, 0.81) 0.44 (0.25, 0.79)
Felbinac vs. Ketoprofen 0.46 (0.26, 0.83) 0.48 (0.27, 0.84)
Piroxicam vs. Ketoprofen 0.42 (0.24, 0.74) 0.43 (0.25, 0.76)
Indomethacin vs. Ketoprofen 0.24 (0.13, 0.46) 0.26 (0.13, 0.48)
Other NSAID vs. Ketoprofen 0.57 (0.34, 0.95) 0.54 (0.33, 0.89)
Felbinac vs. Ibuprofen 1.02 (0.56, 1.86) 1.07 (0.60, 1.92)
Piroxicam vs. Ibuprofen 0.93 (0.52, 1.67) 0.98 (0.55, 1.73)
Indomethacin vs. Ibuprofen 0.54 (0.29, 1.04) 0.58 (0.30, 1.11)
Other NSAID vs. Ibuprofen 1.27 (0.74, 2.15) 1.22 (0.73, 2.04)
Piroxicam vs. Felbinac 0.91 (0.52, 1.60) 0.91 (0.51, 1.59)
Indomethacin vs. Felbinac 0.53 (0.28, 1.01) 0.54 (0.28, 1.02)
Other NSAID vs. Felbinac 1.24 (0.74, 2.08) 1.13 (0.68, 1.88)
Indomethacin vs. Piroxicam 0.58 (0.31, 1.09) 0.59 (0.31, 1.11)
Other NSAID vs. Piroxicam 1.36 (0.82, 2.25) 1.24 (0.76, 2.03)
Other NSAID vs. Indomethacin 2.33 (1.31, 4.15) 2.09 (1.18, 3.70)
Bolded text denotes head-to-head meta-analysis evaluations. * Mixed treatment method identifies a significant effect, adjusted indirect comparison 
does not, adjusted indirect comparison identifies significant effect, mixed treatment comparison does not. ** Direction of effect differs between 
approaches, ***Important effect size differences.
Table 3: Statins for the prevention of cardiovascular mortality[17].
Treatment Comparison Mixed Treatment Comparison Adjusted Indirect Comparison
Odds Ratio 95% Credible Interval Odds Ratio 95% Confidence Intervals
Atorvastatin vs. Placebo 0.88 (0.69, 1.11) 0.88 (0.70, 1.12)
Fluvastatin vs. Placebo 0.77 (0.53, 1.11) 0.77 (0.53, 1.11)
Pravastatin vs. Placebo 0.91 (0.80, 1.03) 0.91 (0.81, 1.02)
Lovastatin vs. Placebo 0.67 (0.35, 1.24) 0.55 (0.31, 0.99)
Fluvastatin vs. Atorvastatin 0.87 (0.56, 1.35) 0.87 (0.56, 1.35)
Pravastatin vs. Atorvastatin 1.03 (0.79, 1.35) 1.03 (0.79, 1.33)
Lovastatin vs. Atorvastatin 0.76 (0.38, 1.47) 0.62 (0.33, 1.15)
Pravastatin vs. Fluvastatin 1.18 (0.80, 1.75) 1.18 (0.79, 1.74)
Lovastatin vs. Fluvastatin 0.87 (0.41, 1.80) 0.71 (0.36, 1.41)
Lovastatin vs. Pravastatin 0.74 (0.39, 1.38) 0.60 (0.33, 1.08)
Bolded text denotes head-to-head meta-analysis evaluations. * Mixed treatment method identifies a significant effect, adjusted indirect comparison 
does not, adjusted indirect comparison identifies significant effect, mixed treatment comparison does not. ** Direction of effect differs between 
approaches, ***Important effect size differences.
Trials 2009, 10:86 http://www.trialsjournal.com/content/10/1/86tically significant difference between the effects of two
treatments, when the adjusted indirect comparison
approach did not.
Analysis 5. Antifungal agents for preventing mortality in solid organ 
transplant recipients[20]
We evaluated the role of antifungal agents for preventing
mortality in solid organ transplant recipients on the basis
of 10 2-arm randomised trials comparing 5 different treat-
ments. The network of evidence for these trials is shown
in Figure 5. The results for the 5 possible pair-wise treat-
ment comparisons using the adjusted indirect compari-
son approach and 10 comparisons using the mixed
treatment comparison are shown in Table 5. In a single
case, the mixed treatment comparison approach found a
different direction of effect than the adjusted indirect
comparison approach. The estimated ORs and associated
uncertainty intervals produced by the two approaches
were importantly different for three pair-wise treatment
comparisons.
Analysis 6. Prophylactic treatments against pneumocystis carinii 
pneumonia and toxoplasma encephalitis in HIV-infected patients[4]
We evaluated 4 different interventions from 22 trials with
44 trial arms, allowing a possible 6 comparisons. See Fig-
ure 6 and Table 6. In this example, the adjusted indirect
comparison was only required for one comparison but
differed importantly from the mixed treatment method.
Analysis 7. Antifungal agents for the prevention of mortality among 
patients with invasive candidemia
(Perri D, O'Regan C, Cooper C, Nachega JB, Wu P, Tleyjeh
I, Philips P, Mills EJ: Antifungal treatment for systemtic
candida infectons: A mixed treatment comparison meta-
analysis. Unpublished.)
We evaluated the effectiveness of 8 different treatments
from 19 trials, allowing 38 arms, for a possible 28 com-
parisons. See Figure 7 and Table 7. For 9 comparisons we
were unable to conduct the adjusted indirect evaluation,
as no suitable mutual comparator existed. The direction of
effect differed between the two approaches in 4 studies. In
one circumstance, the adjusted indirect approach found
significant treatment effect while the mixed treatment
method did not.
Discussion
Our paper presents important evidence on the relative
performance of the adjusted indirect comparison and
mixed treatment comparison approaches to evaluating
multiple health interventions in the absence of sufficient
direct evidence.
For the 3 star-networks considered in this paper, we found
that both approaches led to similar results, as they could
use all the available information in the data. In general,
some slight difference may exist between the results pro-
duced by the two approaches for this type of network
since the adjusted indirect comparison approach uses
(approximate) normal likelihood while the mixed treat-
ment comparison approach uses (exact) binomial likeli-
hood. If one chooses to ignore such a slight difference, the
adjusted indirect comparison approach is easier to use for
star-networks than the mixed treatment comparison
approach.
For the 2 single-loop networks included in this paper, we
found that the adjusted indirect comparison and mixed
treatment comparison approached yielded comparable
estimates of relative treatment effectiveness. However, the
two approaches will be expected to yield different results
for general single-loop networks, simply because the
mixed treatment comparison approach is based on all
available information in the data but the adjusted indirect
comparison approach is not.
Table 4: Topical treatment for treatment of ear discharge at 1 and 2 weeks[21].
Treatment Comparison Mixed Treatment Comparison Adjusted Indirect Comparison
Odds Ratio 95% Credible Interval Odds Ratio 95% Confidence Interval
Topical Quinolone Antibiotic vs. No Treatment 0.13 (0.06, 0.24) 0.08 (0.01, 0.51)
Topical Non-Quinolone Antibiotic vs. No Treatment 0.21 (0.10, 0.44) 0.28 (0.09, 0.52)
Topical Antiseptic vs. No Treatment 0.71 (0.32, 1.55) 0.61 (0.22, 1.22)
Topical Non-Quinolone Antibiotic vs. Topical Quinolone 
Antibiotic
1.67 (1.17, 2.31) 1.62 (0.92, 2.85)
Topical Antiseptic vs. Topical Quinolone Antibiotic 5.64 (3.70, 8.70) 4.31 (1.34, 13.90)
Topical Antiseptic vs. Topical Non-Quinolone Antibiotic 3.37 (2.25, 5.03) 3.02 (0.74, 12.29)*
Bolded text denotes head-to-head meta-analysis evaluations. * Mixed treatment method identifies a significant effect, adjusted indirect comparison 
does not, adjusted indirect comparison identifies significant effect, mixed treatment comparison does not. ** Direction of effect differs between 
approaches, ***Important effect size differences.Page 8 of 12
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ison and the mixed treatment comparison approach pro-
duced comparable estimates of relative treatment
effectiveness for the two multi-loop networks considered
in this paper. As pointed out by one of the referees during
peer-review, in general, the adjusted indirect comparison
approach may be difficult, if not impossible, to apply for
this type of network. As an illustration, suppose we are
interested in the indirect estimate for the OR of the pair-
wise comparison of treatments C and D in Figure 7, where
there is no direct comparison between these two treat-
ments. But, through the network of evidence, there are
three ways to perform the adjusted indirect comparison of
treatments C and D: (1) using comparisons C versus E and
D versus E; (2) using comparisons C versus B and D versus
B; (3) using comparisons C versus B, B versus F, and F ver-
sus D. Clearly, these comparisons will lead to different
results. One possible way to deal with this problem is to
apply the adjusted indirect comparison approach three
times to these data sets respectively and then combine
them together to get a pooled estimate. But, crucially,
these three routes to the estimate of the OR of the pair-
wise comparison of treatments C and D are not in this
case statistically independent. As a result, the resulting
estimates cannot be pooled by a simple weighted average.
The mixed treatment comparisons approach, however,
will combine this information simultaneously and pro-
duce a coherent set of estimates for all the treatment con-
trasts, based on all the data.
The adjusted indirect comparison approach may be pre-
ferred for star-networks, as it is typically easier to imple-
Table 5: Antifungal agents for preventing mortality in solid organ transplant recipients[20].
Treatment Comparison Mixed Treatment Comparison Adjusted Indirect Comparison
Odds Ratio 95% Credible Interval Odds Ratio 95% Confidence Interval
Fluconazole vs. Control 0.81 (0.48, 1.37) 0.94 (0.54, 1.63)
Itraconazole vs. Control 0.90 (0.41, 1.99) 0.49 (0.15, 1.56)
Liposomal Amphotericin B vs. Control 0.50 (0.09, 2.33) 0.54 (0.10, 2.52)
Ketoconazole vs. Control 1.83 (0.38, 8.93) 1.66 (0.41, 6.66)
Intraconazole vs. Fluconazole 1.12 (0.52, 2.41) 1.69 (0.58, 5.33)
Liposomal Amphotericin B vs. Fluconazole 0.62 (0.10, 3.17) 0.57 (0.09, 3.39)
Ketoconazole vs. Fluconazole 2.27 (0.43, 12.09) 1.76 (0.39, 7.94)***
Liposomal Amphotericin B vs. Itraconazole 0.55 (0.09, 3.11) 1.10 (0.14, 8.65)**, ***
Ketoconazole vs. Itraconazole 2.03 (0.35, 11.87) 3.38 (0.54, 21.16)***
Ketoconazole vs. Liposomal Amphotericine B 3.68 (0.41, 35.30) 3.07 (0.34, 27.48)***
Bolded text denotes head-to-head meta-analysis evaluations. * Mixed treatment method identifies a significant effect, adjusted indirect comparison 
does not, adjusted indirect comparison identifies significant effect, mixed treatment comparison does not. ** Direction of effect differs between 
approaches, ***Important effect size differences.
Table 6: Prophylactic treatments against pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients[4].
Treatment Comparison Mixed Treatment Comparison Adjusted Indirect Comparison
Odds Ratio 95% Credible Interval Odds Ratio 95% Confidence Interval
AP vs. TMP-SMX 2.68 (1.90, 3.81) 3.19 (2.02, 5.03)
D vs. TMP-SMX 1.38 (0.94, 2.04) 0.92 (0.58, 1.46)
D/P vs. TMP-SMX 3.02 (1.92, 4.79) 3.22 (1.70, 6.10)
D vs. AP 0.52 (0.34, 0.78) 0.90 (0.53, 1.52)
D/P vs. AP 1.13 (0.71, 1.80) 0.86 (0.47, 1.57)
D/P vs. D 2.19 (1.26, 3.82) 3.5 (1.59, 7.69)***
Bolded text denotes head-to-head meta-analysis evaluations. * Mixed treatment method identifies a significant effect, adjusted indirect comparison 
does not, adjusted indirect comparison identifies significant effect, mixed treatment comparison does not. ** Direction of effect differs between 
approaches, ***Important effect size differences.Page 9 of 12
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provides similar results. For single-loop networks, one
could use either approach, though the results produced by
the two approaches might generally be different, reflecting
the fact that the mixed treatment comparison approach
relies on all of the information available in the data but
the adjusted indirect comparison approach does not. For
multi-loop networks, it might be difficult, if not impossi-
ble, to implement the adjusted indirect comparison
approach in some situations, rendering the mixed treat-
ment comparison as the preferred choice for this type of
network.
There are strengths and limitations that should be consid-
ered when interpreting this manuscript. Strengths include
our extensive searching of systematic reviews and inclu-
sion of unpublished systematic reviews. It is possible that
we missed systematic reviews that may have met our
inclusion criteria, however our searches were extensive,
were supplemented with others' systematic reviews.[2,13]
and were conducted in duplicate to minimize bias. We
applied the fixed effects method for both the adjusted
indirect comparison and mixed treatment comparison
approaches. Our goodness of fit checks indicated that the
fixed effects mixed treatment comparison approach was
Table 7: Antifungal agents for the prevention of mortality among patients with invasive candidemia (Perri D, O'Regan C, Cooper C, 
Nachega JB, Wu P, Tleyjeh I, Philips P, Mills EJ: Antifungal treatment for systemtic candida infectons: A mixed treatment comparison 
meta-analysis. Unpublished)
Treatment Comparison Mixed Treatment Comparison Adjusted Indirect Comparison
Odds Ratio 95% Credible Interval Odds Ratio 95% Confidence Interval
Caspofungin vs. Fluconazole 1.01 (0.60, 1.71) 0.85 (0.44, 1.64)**
Amphotericin B Deoxycholate vs. Fluconazole 1.26 (0.96, 1.65) 1.31 (0.99, 1.74)
Amphotericin B Liposomal vs. Fluconazole 1.20 (0.70, 2.06) - -
Voriconazole vs. Fluconazole 1.20 (0.75, 1.94) 0.58 (0.33, 0.99)*, ***
Micafungin vs. Fluconazole 1.22 (0.68, 2.16) - -
Anidulafungin vs. Fluconazole 0.64 (0.36, 1.14) 0.65 (0.35, 1.19)
Itraconazole vs. Fluconazole 0.89 (0.46, 1.69 0.54 (0.27, 1.05)
Amphotericin B Deoxycholate vs. Caspofungin 1.24 (0.79, 1.94) 1.12 (0.62, 1.12)
Amphotericin B Liposomal vs. Caspofungin 1.19 (0.90, 1.57) 1.31 (0.90, 1.91)
Voriconazole vs. Caspofungin 1.19 (0.75, 1.89) 0.67 (0.32, 1.43)**
Micafungin vs. Caspofungin 1.20 (0.89, 1.62) 1.25 (0.84, 1.88)
Anidulafungin vs. Caspofungin 0.64 (0.29, 1.38) - -
Itraconazole vs. Caspofungin 0.87 (0.41, 1.84 0.63 (0.27, 1.47)
Amphotericin B Liposomal vs. Amphotericin B 
Deoxycholate
0.96 (0.60, 1.53) 1.80 (0.86, 3.76)**
Voriconazole vs. Amphotericin B Deoxycholate 0.96 (0.65, 1.42) 0.76 (0.48, 1.22)
Micafungin vs. Amphotericin B Deoxycholate 0.97 (0.58, 1.61) 0.95 (0.55, 1.64)
Anidulafungin vs. Amphotericin B Deoxycholate 0.51 (0.27, 0.96) 0.49 (0.25, 0.97)
Itraconazole vs. Amphotericin B Deoxycholate 0.70 (0.39, 1.27) 0.71 (0.39, 1.28)
Voriconazole vs. Amphotericin B Liposomal 1.00 (0.64, 1.55) 1.37 (0.77, 2.45)
Micafungin vs. Amphotericin B Liposomal 1.01 (0.75, 1.35) 0.96 (0.66, 1.40)
Anidulafungin vs. Amphotericin B Liposomal 0.54 (0.24, 1.17) - -
Itraconazole vs. Amphotericin B Liposomal 0.74 (0.34, 1.57) - -
Micafungin vs. Voriconazole 1.01 (0.61, 1.67) - -
Anidulafungin vs. Voriconazole 0.54 (0.25, 1.13) - -
Itraconazole vs. Voriconazole 0.74 (0.36, 1.50) 0.93 (0.43, 1.98)
Anidulafungin vs. Micafungin 0.53 (0.24, 1.19) - -
Itraconazole vs. Micafungin 0.73 (0.33, 1.59) - -
Itraconazole vs. Anidulafungin 1.37 (0.58, 3.26) - -
Bolded text denotes head-to-head meta-analysis evaluations. * Mixed treatment method identifies a significant effect, adjusted indirect comparison 
does not, adjusted indirect comparison identifies significant effect, mixed treatment comparison does not. ** Direction of effect differs between 
approaches, ***Important effect size differences.Page 10 of 12
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ther sensitivity analyses performed for this approach con-
firmed the robustness of the overall conclusions to the
exclusion of discrepant trials. It is possible that we would
have found slight differences if we had employed the ran-
dom effects method. More often than not however, these
methods yield comparable estimates of relative treatment
effects.[18] Some have argued that the fixed effects
method should now be preferred over a random effects
method as it places a greater weight on larger studies, thus
studies may have reduced bias.[23] Finally, we were una-
ble to compare the adjusted indirect comparison
approach with the head-to-head evaluations as, in this set
of systematic reviews, there was an insufficient number of
trials with more than one comparator.
Salanti and others have discussed the merits and chal-
lenges of the mixed treatment approach.[12,23,24] The
mixed treatment comparison is a resource intensive
approach to conducting analyses as it requires knowledge
of Bayesian principles and working abilities with Win-
BUGS, a somewhat user-unfriendly software for those
unfamiliar with it. However, the mixed treatment
approach also provides interesting additional informa-
tion that may be useful to some readers. Additional infor-
mation includes probabilities of a ranking order of the
effectiveness of interventions. For the sake of clarity, we
haven't presented the probabilities associated with each
analysis. Probabilities may be difficult to interpret
though, particularly when there are not clear differences
amongst them. A further additional source of information
is that this analysis provides indirect comparisons without
requiring a mutual comparator, a possible strength over
the adjusted indirect approach. However, we cannot know
whether this estimate is reliable or similar to an adjusted
indirect approach until further trials become available.
Finally, some have argued that the mixed treatment com-
parison is a 'black-box,' as it may be difficult or impossible
to determine where an analysis has gone incorrectly.[25]
Future validations of the analytic manner performed in
this manuscript may yield insights into the transparency
of this method. Finally, no reporting guidelines exist for
the mixed treatment approach. A step forward may be the
development of minimum reporting criteria for this
approach.[11,12]
For less complex analyses, such as star-shaped networks,
the adjusted indirect comparison may be easier for meta-
analysts to apply in their general practice. One of us (GG)
was involved in the development of this approach.[4] The
adjusted indirect comparison is limited in more complex
evaluations, as compared to the mixed treatment compar-
ison, as it requires the utilization of a mutual comparator
when performing indirect comparisons. However, as dis-
cussed above, the validity of indirect comparisons without
mutual comparators that are performed via the mixed
treatment comparison approach may be reasonably ques-
tioned. The adjusted indirect comparison approach
requires the knowledge of standard meta-analysis tech-
niques and working knowledge of programmable soft-
ware such as R, S-Plus, Stata or SAS, so is arguably also
resource intensive. A recent free download of a simple
software may make this approach accessible for non-stat-
isticians.[25,26]
There is also concern that both the adjusted indirect com-
parison and mixed treatment comparison approaches will
have less power than the direct approach and may some-
times lead to indeterminate results, in the form of wide
uncertainty intervals for relative intervention effects.
Inferences based on such findings may therefore be lim-
ited. In addition, it is not clear yet how to interpret results
that differ substantially between the two approaches.
Finally, although the choice of approach may differ only
marginally in treatment effect estimates, the impact of
small differences may affect future analyses based on
study findings, such as cost-effectiveness models. There is
a clear need to evaluate whether one method may impor-
tantly impact cost-effectiveness projections over
another.[11]
Conclusion
In conclusion, both the mixed treatment comparison
approach and the adjusted indirect comparison approach
provide compelling inferences about the relative effective-
ness of interventions. In less complex indirect compari-
sons, where a mutual comparator exists, the adjusted
indirect comparison may be favourable due to its simplic-
ity. In more complex models, the mixed treatment com-
parison appears to offer benefits for comparisons that
other methods cannot.
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